CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
21 hedge funds and large institutions have $15.1M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Holders
21
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$669K | |
| 2 | +$86.6K | |
| 3 | +$84.9K | |
| 4 |
Morgan Stanley
New York
|
+$10.9K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$6.32K |
Top Sellers
| 1 | -$323K | |
| 2 | -$100K | |
| 3 | -$49.6K | |
| 4 |
LWP
Legacy Wealth Partners
Calabasas,
California
|
-$17.1K |
| 5 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
-$12.4K |